CTR20260918 Recombinant anti-human EGFR antibody/IL-10 bispecific FC fusion protein(Dingfu B Malignant Pleural Effusion Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines CTR20260918 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 27 August 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why CTR20260918 is a hot trial to watch
Malignant Pleural Effusion is being segmented by mechanism, treatment setting, geography and endpoint architecture. CTR20260918 is notable because it evaluates Recombinant anti-human EGFR antibody/IL-10 bispecific FC fusion protein(Dingfu B in a Phase 2 design sponsored by Shihuida Pharmaceutical Group (Jilin) Co., Ltd.. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | CTR20260918 |
| Official title | 一项评估DF203注射液在恶性胸腔积液患者中的有效性和安全性的随机、对照、开放、多中心II期临床研究 |
| Phase / status | Phase 2 / 进行中 （招募中） |
| Intervention | Recombinant anti-human EGFR antibody/IL-10 bispecific FC fusion protein(Dingfu B |
| Sponsor | Shihuida Pharmaceutical Group (Jilin) Co., Ltd. |
| Geography | China |
| Enrollment | 1 |
| Primary endpoint | |
| Endpoint time frame | 4~6周 |
| Primary completion / readout proxy | Not reported |
Protocol design and endpoint interpretation
The indexed record describes a Phase 2 study of Recombinant anti-human EGFR antibody/IL-10 bispecific FC fusion protein(Dingfu B in Malignant Pleural Effusion.
Allocation is 随机化, masking is 开放, and the intervention model is 平行分组. Planned enrollment of 1 participants across China shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- Primary endpoint (4~6周) — 无穿刺生存期（PuFS）
Readout outlook and evidence gap
The current protocol points to Not reported as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset MCP profile: Recombinant anti-human EGFR antibody/IL-10 bispecific FC fusion protein(Dingfu B is indexed as No normalized modality returned, with target No normalized target returned, mechanism No normalized mechanism returned, and global highest development status No normalized global status returned.
Company & Deal Intelligence MCP profile: Shihuida Pharmaceutical Group (Jilin) Co., Ltd. is resolved to a normalized organization record in Baishan, China. The organization workflow adds identity, location, portfolio and partnering context where available.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
CTR20260918 provides a focused lens on Malignant Pleural Effusion development. Its value will be determined by whether Recombinant anti-human EGFR antibody/IL-10 bispecific FC fusion protein(Dingfu B can convert the current Phase 2 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
